False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
The United States filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals Inc. (Regeneron), a New York-based pharmaceutical company. Regeneron manufactures and sells Eylea, an anti-vascular endothelial growth factor inhibitor approved by the Food and Drug Administration to treat, among other conditions, neovascular Age-Related Macular Degeneration, a prevalent, usually age-related condition that impairs vision.
More About This Action
Action Details
- Date:April 10, 2024
- Agency:U.S. Department of Justice and U.S. Attorney's Office, District of Massachusetts
-
Enforcement Types:
- Criminal and Civil Actions